Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Total Current Liabilities (2016 - 2025)

Tg Therapeutics has reported Total Current Liabilities over the past 10 years, most recently at $153.8 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $153.8 million for Q4 2025, up 69.57% from a year ago — trailing twelve months through Dec 2025 was $153.8 million (up 69.57% YoY), and the annual figure for FY2025 was $153.8 million, up 69.57%.
  • Total Current Liabilities for Q4 2025 was $153.8 million at Tg Therapeutics, down from $156.8 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for TGTX hit a ceiling of $171.9 million in Q2 2025 and a floor of $36.4 million in Q3 2022.
  • Median Total Current Liabilities over the past 5 years was $87.6 million (2021), compared with a mean of $91.7 million.
  • Biggest five-year swings in Total Current Liabilities: plummeted 58.42% in 2022 and later skyrocketed 116.92% in 2024.
  • Tg Therapeutics' Total Current Liabilities stood at $65.4 million in 2021, then decreased by 18.63% to $53.2 million in 2022, then grew by 0.98% to $53.7 million in 2023, then soared by 68.8% to $90.7 million in 2024, then surged by 69.57% to $153.8 million in 2025.
  • The last three reported values for Total Current Liabilities were $153.8 million (Q4 2025), $156.8 million (Q3 2025), and $171.9 million (Q2 2025) per Business Quant data.